Skip to contentL
Lineage Cell Therapeutics, Inc.
L
LCTXLineage Cell Therapeutics, Inc. Q2 2017 · 10-Q
Revenue$381.00K$381.00K−67.5% vs Q2 2016 Net Income-$11.65M-$11.65MN/M vs Q2 2016 EPS Diluted-$0.11-$0.11N/M vs Q2 2016 Gross Profit$376,000−67.9% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lineage Cell Therapeutics, Inc. · CIK 876343 · Engraved from SEC EDGAR
Operating Cash Flowderived-$9,063,000N/M Free Cash Flowderived-$9,322,000— Margins · derivedGross margin98.7%−1.3 pt vs Q2 2016
Operating margin-2708.1%−1478.2 pt vs Q2 2016
Net margin-3058.0%
ended Jun 30, 2017 · filed Aug 9, 2017 · 40 d after period end